0.0036EUR-5.26%Mkt Cap: 319288 EURP/E: —Last update: 2026-06-01
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic at…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap319.29K EUR
Enterprise Value10.84M EUR
Revenue (TTM)2.00K EUR
Gross Profit555.00K EUR
Net Income (TTM)-3.73M EUR
Revenue/Share0.0000 EUR
Last Price0.0036 EUR
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees11
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0003846632
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
EV/EBITDA11.89
EV/Revenue5420.90
P/S168.51
P/B-0.00
EPS (TTM)-0.13
EPS (Forward)-0.47
52W Range
0.00360% of range0.0840
52W High0.0840 EUR
52W Low0.0036 EUR
Profitability
Gross Margin100.00%
Oper. Margin45050.00%
EBITDA Margin45600.00%
Profit Margin-671.71%
ROE28.92%
ROA-97.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.71M EUR
CapEx (TTM)—
FCF Margin-110843.75%
FCF Yield-694.32%
Net Debt10.82M EUR
Net Debt/EBITDA11.87
Balance Sheet
Debt/Equity-0.89
Current Ratio0.17
Quick Ratio0.17
Book Value/Sh-2.4250 EUR
Cash/Share0.0010 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10000
Split DateSep 3, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.88.69M
Float4.28M
Insiders9.67%
Institutions0.00%
Technical
SMA 500.0043 (-16.7%)
SMA 2000.0102 (-64.6%)
Beta-0.15
S&P 52W Chg27.94%
Avg Vol (30d)833.55K
Avg Vol (10d)1.68M
Technical Indicators
RSI (14)46.7
MACD-0.0001
MACD Signal-0.0002
MACD Hist.+0.0001
BB Upper0.0042 EUR
BB Middle0.0038 EUR
BB Lower0.0035 EUR
BB Width19.49%
ATR (14)0.0006 EUR
Vol Ratio (20d)0.33x